ALB and gallbladder cancer: Thus, these results indicate that HSA normalization does not reduce the error in AFB1-lys internal dose estimates in the setting of hepatic disease secondary to gallbladder cancer, but likely adds technical variance, reducing estimate precision and potentially increasing the risk of a type 2 error in statistical inference.